Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Robert Gunnell

Geriatric Medicine Grant, MI Medical Doctor

NPI 1225066079 CMS profile 146414

230 S Maple St, Grant, MI 49327

Open in the dashboard

General payments

$563

32 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Robert Gunnell of Grant, MI is reported in the CMS Open Payments database as having received $563 across 32 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 70th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $124 7
2022 General $59 3
2021 General $24 1
2020 General $17 1
2019 General $338 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Gunnell
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Robert Gunnell were reported at $0. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Robert Gunnell Geriatric Medicine median Middle half National median
2019 $338 $96 $28–$339 $163
2020 $17 $99 $28–$262 $114
2021 $24 $94 $27–$318 $132
2022 $59 $103 $34–$338 $149
2023 $124 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $0 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Neurocrine Biosciences, Inc. $92 5 payments
  2. Otsuka America Pharmaceutical, Inc. $88 5 payments
  3. Vanda Pharmaceuticals Inc. $85 4 payments
  4. Janssen Pharmaceuticals, Inc $69 4 payments
  5. Alkermes, Inc. $66 4 payments
  6. Indivior Inc. $58 4 payments
  7. Lundbeck LLC $31 2 payments
  8. AbbVie, Inc. $28 2 payments
  9. Teva Pharmaceuticals USA, Inc. $24 1 payment
  10. Axsome Therapeutics, Inc. $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $563 32 payments
Products named General payments · program years 2019–2023
  1. FANAPT $85 4 payments
  2. HETLIOZ $85 4 payments
  3. INVEGA TRINZA $69 4 payments
  4. INGREZZA $62 4 payments
  5. SUBLOCADE $58 4 payments
  6. INVEGA SUSTENNA $55 3 payments
  7. REXULTI $50 3 payments
  8. LYBALVI $49 3 payments
  9. ARISTADA Cns $49 3 payments
  10. ARISTADA Cns $49 3 payments
  11. Other $306 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 94 drugs

Part D claims

3,617

Median for Family Practice: 1,826

Drug cost

$223,527

Median for Family Practice: $120,094

Branded share of claims

21.8%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 198 $103,055
Vraylar Cariprazine Hcl Brand 25 $18,341
Myrbetriq Mirabegron Brand 24 $11,433
Xarelto Rivaroxaban Brand 15 $8,844
Creon Lipase/Protease/Amylase Brand 12 $8,781
Spiriva Respimat Tiotropium Bromide Brand 12 $6,561
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $6,307
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 70 $4,127
Metoprolol Succinate Generic 120 $3,532
Fentanyl Generic 23 $2,921

The 10 drugs with the highest cost, of 94 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$32,570

Medicare's payments for the services billed

Medicare patients

35

Average age 87

Services billed

362

22 women, 13 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Alzheimer's or dementia 74%
High blood pressure 60%
Depression 57%
Chronic kidney disease 49%
Arthritis 46%
Heart failure 37%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

32 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record